GlobeNewswire: EDAP TMS S.A. Contains the last 10 of 397 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T10:45:21ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/13/2845298/0/en/EDAP-to-Announce-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-March-27-2024.html?f=22&fvtc=4&fvtv=7538EDAP to Announce Fourth Quarter and Full-Year 2023 Financial Results on March 27, 20242024-03-13T11:00:00Z<![CDATA[Company to host conference call and webcast on Wednesday, March 27th at 8:30am EDT]]>https://www.globenewswire.com/news-release/2024/03/06/2841240/0/en/EDAP-to-Present-at-the-Oppenheimer-34th-Annual-Healthcare-MedTech-Services-Conference.html?f=22&fvtc=4&fvtv=7538EDAP to Present at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference2024-03-06T12:00:00Z<![CDATA[LYON, France, March 6, 2024 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a virtual presentation and host 1x1 investor meetings at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference, which is being held virtually from March 12-13, 2024.]]>https://www.globenewswire.com/news-release/2024/03/04/2839402/0/en/EDAP-Announces-FDA-Breakthrough-Device-Designation-for-Focal-One-in-the-Treatment-of-Deep-Infiltrating-Rectal-Endometriosis.html?f=22&fvtc=4&fvtv=7538EDAP Announces FDA Breakthrough Device Designation for Focal One® in the Treatment of Deep Infiltrating Rectal Endometriosis2024-03-04T12:00:00Z<![CDATA[Focal One HIFU has potential to address large market impacting thousands of women each year]]>https://www.globenewswire.com/news-release/2024/02/29/2837820/0/en/EDAP-Announces-Record-Preliminary-Fourth-Quarter-and-Full-Year-2023-Revenues.html?f=22&fvtc=4&fvtv=7538EDAP Announces Record Preliminary Fourth Quarter and Full-Year 2023 Revenues2024-02-29T12:00:00Z<![CDATA[LYON, France, February 29, 2024 - EDAP TMS SA (Nasdaq: EDAP), a global leader in robotic energy-based therapies, today announced preliminary unaudited fourth quarter and full-year 2023 revenues.]]>https://www.globenewswire.com/news-release/2024/02/01/2821937/0/en/EDAP-Announces-Completion-of-Enrollment-in-Phase-3-Study-Evaluating-Focal-One-HIFU-Therapy-for-the-Treatment-of-Deep-Infiltrating-Rectal-Endometriosis.html?f=22&fvtc=4&fvtv=7538EDAP Announces Completion of Enrollment in Phase 3 Study Evaluating Focal One HIFU Therapy for the Treatment of Deep Infiltrating Rectal Endometriosis2024-02-01T13:00:00Z<![CDATA[LYON, France, February 1, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced today that it has completed enrollment in its Phase 3 study (Endo-HIFU-R2) evaluating Focal One High-Intensity Focused Ultrasound (HIFU) therapy for the treatment of deep infiltrating rectal endometriosis. The ongoing Phase 3 study (NCT05755958) is a comparative, randomized, double blind trial, with the primary objective of evaluating acute pelvic pain levels in 60 patients. Select treated patients are followed three months post-HIFU treatment in comparison to a sham group. The last patient was treated in January. Study results are expected in the second half of 2024.]]>https://www.globenewswire.com/news-release/2024/01/08/2805370/0/en/EDAP-Announces-Preliminary-Fourth-Quarter-Record-Focal-One-System-Sales-and-Placements.html?f=22&fvtc=4&fvtv=7538EDAP Announces Preliminary Fourth Quarter Record Focal One® System Sales and Placements2024-01-08T13:00:00Z<![CDATA[Company reports preliminary placement results of twelve Focal One Systems, inclusive of ten capital sales]]>https://www.globenewswire.com/news-release/2024/01/02/2802606/0/en/EDAP-Appoints-Ken-Mobeck-Global-Chief-Financial-Officer-and-Francois-Dietsch-Global-Chief-Accounting-Officer.html?f=22&fvtc=4&fvtv=7538EDAP Appoints Ken Mobeck, Global Chief Financial Officer, and Francois Dietsch, Global Chief Accounting Officer2024-01-02T13:00:00Z<![CDATA[]]>https://www.globenewswire.com/news-release/2023/12/12/2794688/0/en/EDAP-Announces-Positive-Opinion-for-Reimbursement-from-the-French-National-Authority-for-Health-HAS-for-HIFU-treatment-of-Prostate-Cancer.html?f=22&fvtc=4&fvtv=7538EDAP Announces Positive Opinion for Reimbursement from the French National Authority for Health (HAS) for HIFU treatment of Prostate Cancer2023-12-12T13:00:00Z<![CDATA[Represents Key Milestone Toward Universal Coverage for Focal One HIFU in France]]>https://www.globenewswire.com/news-release/2023/12/06/2792122/0/en/EDAP-Appoints-Lance-Willsey-M-S-M-D-to-Board-of-Directors.html?f=22&fvtc=4&fvtv=7538EDAP Appoints Lance Willsey, M.S., M.D. to Board of Directors2023-12-06T21:30:00Z<![CDATA[LYON, France, December 6, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced the appointment of Lance Willsey, M.S., M.D. to its Board of Directors. Dr. Willsey replaces Dr. Argil Wheelock who has resigned as director of the Company.]]>https://www.globenewswire.com/news-release/2023/11/30/2788541/0/en/EDAP-Receives-2023-Industry-Category-Award-from-the-French-National-Institute-for-Intellectual-Property-INPI-for-Its-Therapeutic-Ultrasound-Technology.html?f=22&fvtc=4&fvtv=7538EDAP Receives 2023 Industry Category Award from the French National Institute for Intellectual Property (INPI) for Its Therapeutic Ultrasound Technology2023-11-30T13:00:00Z<![CDATA[LYON, France, November 30, 2023 - EDAP TMS SA (Nasdaq: EDAP), (“EDAP”), the global leader in robotic energy-based therapies, today announced that is has received the Industry Category Award from the French National Institute for Intellectual Property (INPI) based on the Company’s innovative therapeutic ultrasound technology. On November 23, 2023, the jury for the 2023 edition of the INPI Trophies honored five companies at an awards ceremony in Paris, which spanned five different categories: Export, Industry, Start-up, Responsible Innovation, and Partnership Research.]]>